Clinical Trial Update: Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cryoablation with sintilimab and lenvatinib as first-line therapy for advanced intrahepatic cholangiocarcinoma; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Cryoablation
• Lenvatinib (lenvatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN